Buy Growth Secretagogues for Growth Hormone & Muscle Growth

Within the broader growth hormone secretagogue category, a smaller set of compounds is specifically associated with muscle and body composition research, rather than growth hormone signalling more generally. 

Tesamorelin and the CJC-1295 and Ipamorelin pairing are the two most frequently referenced examples in this narrower area of study, alongside IGF-1 LR3, which works through a fundamentally different route (see below).

Tesamorelin

Research on Tesamorelin has centred on body composition outcomes in clinical trial populations. Falutz and colleagues (2007), writing in the New England Journal of Medicine, reported that Tesamorelin significantly reduced visceral adipose tissue, the metabolically active fat stored around internal organs, over a 26-week randomised trial in 412 adults with HIV-associated lipodystrophy (Falutz et al., 2007).

A more recent meta-analysis pooling five randomised controlled trials of Tesamorelin in this same population found the visceral fat reduction was sustained over 26 to 52 weeks, at roughly 15 to 20 percent, with no significant change in subcutaneous fat (the fat stored just under the skin, rather than around the organs) or body mass index (BMI, a general measure of weight relative to height), alongside a modest increase in lean body mass (muscle and other non-fat tissue) of around 1.4 kg (Badran et al., 2026).

This finding is specific to that clinical population and to Tesamorelin’s GHRH mechanism, meaning it works by mimicking the natural hormone that tells the pituitary gland (a small gland at the base of the brain that releases growth hormone) to release growth hormone. It doesn’t extend to a general claim about fat loss or muscle gain in a healthy research subject.

IGF-1 LR3

A mechanistically distinct compound worth separating out is IGF-1 LR3, a modified, long-acting analogue of IGF-1 itself, catalogued under our Energy & Metabolic Peptides category rather than this one, though it’s frequently discussed alongside growth hormone secretagogues given how directly its mechanism relates to theirs. 

The secretagogues covered above all work upstream: they raise the pituitary’s output of growth hormone, which then signals the liver and other tissues to produce IGF-1, the hormone that carries out much of GH’s downstream effect on muscle. IGF-1 LR3 skips that signalling chain entirely. Rather than prompting the body to produce more IGF-1, it acts as IGF-1, engaging IGF-1 receptors on muscle tissue directly.

In animal research, this direct route has produced measurable effects. Barton-Davis and colleagues (1998), publishing in the Proceedings of the National Academy of Sciences, found that local IGF-1 overexpression in mouse skeletal muscle increased muscle mass by around 15% and strength by around 14%, an effect the authors attributed to activation of satellite cells, the muscle’s own resident stem cells (Barton-Davis et al., 1998). 

This is preclinical, animal-model evidence rather than a demonstrated human outcome, but it illustrates why IGF-1 LR3 is studied separately from the secretagogues covered above: its research interest sits downstream of the entire GH axis, engaging muscle tissue directly rather than working through it.

Broader Research

Human research on growth hormone secretagogues more broadly shows that raising GH and IGF-1 (insulin-like growth factor 1, a hormone that carries out many of growth hormone’s effects on the body) levels increases collagen synthesis, the production of collagen, the structural protein that forms the scaffolding of tendons and connective tissue, in tendon and skeletal muscle tissue.

Doessing and colleagues (2010), writing in The Journal of Physiology, found this effect was limited to the collagen matrix rather than the myofibrillar proteins, the fibres inside muscle cells that actually contract to produce force and drive muscle growth (Doessing et al., 2010). This distinction is why the muscle-growth angle is treated as an area needing further high-quality evidence, rather than an established use case.

Current research within this category commonly covers:

• Body composition changes: Visceral and subcutaneous fat mass, and lean body mass, typically measured by CT or DEXA scanning (specialist imaging scans that measure fat and muscle separately, far more precisely than body weight alone) in clinical trial settings.
• Connective tissue synthesis: Collagen production in tendon and skeletal muscle, distinct from the myofibrillar proteins that drive muscle fibre growth itself.
• Growth hormone pulse dynamics: How GHRH analogues and GHRP-type secretagogues each shape the timing and amplitude (how large each burst is) of natural growth hormone release.
• Direct IGF-1 pathway engagement: Compounds such as IGF-1 LR3 that act on IGF-1 receptors directly, independent of the pituitary-driven GH cascade covered above.

Peptides occasionally discussed alongside growth hormone secretagogues in muscle-growth research are catalogued under different categories on this site. AOD-9604, a growth hormone-derived fragment studied for a direct effect on fat metabolism rather than pituitary GH release, and IGF-1 LR3, covered above, both sit within our Energy & Metabolic Peptides category.